# Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress

> **NCT01731093** · PHASE1 · COMPLETED · sponsor: **Alltech Life Sciences Inc.** · enrollment: 24 (actual)

## Conditions studied

- Oxidative Stress

## Interventions

- **DRUG:** AT-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01731093
- **Lead sponsor:** Alltech Life Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-10
- **Final completion:** 2013-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01731093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01731093, "Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT01731093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*